Migraine is a type of a severe headache that is characterized by the intense throbbing in one area of the head. According to National Institute of Neurological Disorders and Stroke, migraine is three times common in women than in men and it is heralded by visual disturbances such as zig-zag lines vision and flashing lights. People having migraine generally have frequent attacks that cause, anxiety, stress, hormonal level changes, and lack of sleep. The duration of migraine pain ranges from four hours to three days. In some cases, people become extremely sensitive to light and sound. There are two treatment approaches established, relieving the symptoms and preventing the attacks. Allodynic Therapeutics, LLC is in the process of developing ALLOD-2 as pro-inflammatory cytokines release inhibitors for the treatment of migraine. Allergan plc is in the process of developing AGN 241689 as a calcitonin gene-related peptide antagonist for the treatment of migraine. Some of the companies having the pipeline of migraine include Amgen plc, Eli Lilly and Company, Alder Biopharmaceuticals, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.